The Relationship of Serum Soluble Fas Ligand (sFasL) Level with the Extent of Coronary Artery Disease

Abstract

Fas/Fas ligand system contributes to the programmed cell death induced by myocardial ischemia. We investigated whether serum soluble Fas ligand (sFasL) level is independently related with the severity and extent of angiographically assessed coronary artery disease (CAD). We included 169 patients in this study. Two groups were formed based on the existence of a lesion on coronary angiography. First group included patients with normal coronary arteries (NCA; n = 53). Patients with atherosclerotic lesions were included in the second group (n = 116). We used the coronary vessel score (the number of the coronary arteries with a lesion leading to ≥ 50% luminal obstruction) and the Azar score to determine the extent and the severity of CAD. Standard enzyme-linked immunosorbent assay kits were used to measure serum sFasL levels. The serum sFasL level was higher in patients with CAD than in patients with NCA (0.52 ± 0.23 mU/mL vs. 0.45 ± 0.18 mU/mL, p = 0.023). The sFasL level correlated with Azar score (r = 0.231, p = 0.003) and with coronary vessel score (r = 0.269, p < 0.001). In the multivariate analysis, we found that age (beta: 0.188, p = 0.008), gender (beta: 0.317, p < 0.001), diabetes mellitus (DM; beta: 0.195, p = 0.008), and sFasL level (beta: 0.209, p = 0.003) were independently related with Azar score. When we used coronary vessel score as the dependent variable, we found that age (p = 0.020), gender (p < 0.001), DM (p = 0.006), and sFasL level (p = 0.001) were independent predictors. Serum sFasL level is associated with angiographically more severe CAD. Our findings suggest that sFasL level may be a biochemical surrogate of severe coronary atherosclerosis.

Keywords

soluble fas ligand - ischemic heart disease - atherosclerosis - apoptosis

Note

This study was supported by the Scientific Investigation Projects Department of Gazi University.

• References

• 1 Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 1998; 97 (23) 2307-2315
• 2 Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001; 88 (10) 998-1003
• 3 Nagata S. Apoptosis by death factor. Cell 1997; 88 (3) 355-365
• 4 French LE, Hahne M, Viard I , et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133 (2) 335-343
• 5 Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4 (4) 415-420
• 6 Nagata S, Golstein P. The Fas death factor. Science 1995; 267 (5203) 1449-1456
• 7 Jeremias I, Kupatt C, Martin-Villalba A , et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation 2000; 102 (8) 915-920
• 8 Kayagaki N, Kawasaki A, Ebata T , et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182 (6) 1777-1783
• 9 Okura T, Watanabe S, Jiang Y , et al. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002; 20 (5) 895-898
• 10 Shimizu M, Fukuo K, Nagata S , et al. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol 2002; 39 (4) 585-590
• 11 Azar RR, Aoun G, Fram DB, Waters DD, Wu AHB, Kiernan FJ. Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. Am J Cardiol 2000; 86 (2) 205-207
• 12 Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4 (4) 415-420
• 13 Kalela A, Koivu TA, Sisto T , et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 62 (5) 337-342
• 14 Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 2005; 35 (9) 537-545
• 15 Schneider P, Holler N, Bodmer JL , et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187 (8) 1205-1213
• 16 Blanco-Colio LM, Martín-Ventura JL, Sol JM, Díaz C, Hernández G, Egido J. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 2004; 43: 1188-1194
• 17 Blanco-Colio LM, Martín-Ventura JL, de Teresa E , et al; ACTFAST investigators. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 2007; 27 (1) 168-174
• 18 Blanco-Colio LM, Martín-Ventura JL, Tuñón J, García-Camarero T, Berrazueta JR, Egido J. Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease: a novel biomarker of endothelial function?. Atherosclerosis 2008; 201: 407-412
• 19 Esaki T, Hayashi T, Muto E , et al. Expression of inducible nitric oxide synthase and Fas/Fas ligand correlates with the incidence of apoptotic cell death in atheromatous plaques of human coronary arteries. Nitric Oxide 2000; 4 (6) 561-571
• 20 Hansson GK, Geng YJ, Holm J, Hårdhammar P, Wennmalm A, Jennische E. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994; 180 (2) 733-738
• 21 Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001; 103 (25) 3099-3104
• 22 Setsuta K, Seino Y, Ogawa T, Ohtsuka T, Seimiya K, Takano T. Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. Circ J 2004; 68 (8) 747-750
• 23 Masse M, Hébert MJ, Troyanov S, Vigneault N, Sirois I, Madore F. Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients. Nephrol Dial Transplant 2002; 17 (3) 485-491
• 24 Hébert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis 2001; 38 (6) 1271-1276
• 25 van der Meer IM, Oei HH, Hofman A, Pols HAP, de Jong FH, Witteman JCM. Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. The Rotterdam Coronary Calcification Study. Atherosclerosis 2006; 189 (2) 464-469
• 26 Van de Werf F, Bax J, Betriu A , et al; ESC Committee for Practice Guidelines (CPG) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945
• 27 Bassand JP, Hamm CW, Ardissino D , et al; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28 (13) 1598-1660